VivoSeq
Immunology

Kidney Transplant Rejection

8

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Kidney Transplant Rejection is an early-stage landscape with 8 programs across 6 companies. The most active players are Sanofi, Sangamo Therapeutics, Veloxis Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

PreclinicalS

Sangamo Therapeutics

1 program

PreclinicalV

Veloxis Pharmaceuticals

1 program

PreclinicalRoche logo

Roche

1 program

PreclinicalNovartis logo

Novartis

1 program

PreclinicalPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical8

Frexalimab

Sanofi

Tacrolimus

Veloxis Pharmaceuticals

Rabbit Anti-Thymocyte Globulin

Sanofi

Mycophenolate Mofetil

Roche

Mycophenolate Sodium

Novartis

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients
Completed·SSangamo Therapeutics·Preclinical·NCT04817774·26 enrolled
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Recruiting·Sanofi logoSanofi·Preclinical·NCT07412470·526 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)